Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers of the world and causes about one million deaths annually (1, 2) . The optimum therapy for patient with HCC is surgical excision either by hepatic resection or orthotropic liver transplantation. Unfortunately many patients are not candidate for surgical resection and efforts have been made to provide various alternative therapies to treat the unresectable HCC. Radiofrequency ablation (RFA) is a technique that is recently developed for the ablation of liver tumours. It converts radio frequency waves into thermal energy, causing coagulation necrosis of the tumours. It has attracted great interest in recent years because of excellent response rate with little morbidity (3, 4) . Compared with other local ablative modalities, RFA has been shown to be safer and more effective (5, 6) .
Positron emission tomography (PET) with 18 F-fluoro-2-deoxy-D-glucose ( 18 F-FDG) is a functional imaging tool that provides metabolic information of the lesion. It is effective for diagnosis, monitoring therapy and detection of recurrent tumours of various cancers because of its high sensitivity and specificity (7) (8) (9) (10) . However, it is less successful in the detection of primary HCC because of variable uptake (11, 12) . Even though the value of 18 F-FDG PET for the detection of primary HCC remains controversial, 18 F-FDG PET would seem to be appropriate for the follow-up of liver tumours (13, 14) . In a recent study, Antoch et al mentioned that homogeneous tracer utilization was found in the area surrounding the lesion on 18 F-FDG PET and PET/CT (15) . There was no area of focal or rim-like increase in the glucose metabolism where a rim-like increase in the contrast enhancement was found by the morphologic imaging immediately after RFA. Therefore 18 F-FDG PET seems to be accurate for the assessment of patients shortly after RFA, although there is no clear consensus on which imaging technique is most reliable to monitor RFA therapy. The purpose of this preliminary study was to evaluate the role of 18 F-FDG PET to assess the earlier recurrence of HCC treated with RFA as compared with CT.
Materials and methods
Patients. This study was performed on 33 lesions in 24 patients with HCC (16 male and 8 female, age range from 50 to 77 years, median age 67 years) who underwent 18 F-FDG  PET imaging and clinical follow-up between April 2000 and  March 2005. 18 F-FDG PET and computed tomography (CT) studies were performed on all patients before treatment with RFA. The time interval between 18 F-FDG PET examination and RFA was 1-4 weeks (mean 2.1 weeks). Biopsy or surgical resection confirmed the histological diagnosis as shown in Table I . Three patients underwent subsegmentectomy and 3 patients had transhepatic arterial embolization (TAE) before the RFA. Nine patients had multiple HCCs. All patients underwent RFA and were followed up at least 2 years with 18 F-FDG PET and CT. Clinical evaluation was performed every 3 months in the first year and every 6 months in the second year. Detectability of recurrence was compared between 18 F-FDG PET and CT in these periods. The study protocols have been approved by the Institutional Review Board of our institute and informed consent was obtained from all patients participating in this study.
18 F-FDG PET study. PET study was performed using a SET2400W PET scanner (Shimadzu Corp., Kyoto, Japan) with a 59.5 cm transaxial field of view and 20 cm axial field of view. The scanner produced 63 image planes, spaced 3.125 mm apart. Transaxial spatial resolution was 4.2 mm full width half-maximum (FWHM) at the center of the field of view, and axial resolution was 5.0 mm FWHM. The blood glucose level in all patients was <110 mg/dl at the time of the 18 F-FDG injection. 18 F-FDG was synthesized by the method of Hamacher et al (16) .
Patients fasted for at least 6 h before 18 F-FDG PET scanning. None of the patients had insulin-dependent diabetes. Data acquisition was initiated at 60 min after the injection of 5-6 MBq/kg 18 F-FDG by the simultaneous emission-transmission method with a rotating external source for absorption correction. Four to five bed positions from the head to the thigh were imaged for eight minutes per position. The attenuation-corrected transaxial images were reconstructed by the ordered subsets expectation maximization (OSEM) algorithm into a 128x128 matrix with pixel dimensions of 4.0 mm in a plane and 3.125 mm axially. Finally, every three consecutive slices were added to generate a transaxial image Table I . Clinical characteristics and the results of 18 F-FDG PET in 24 patients with hepatocellular carcinoma (HCC). 
M, male; F, female; AFP, serum concentration of alpha-fetoprotein; Well diff, well differentiated HCC; Mod diff, moderately differentiated HCC; Poorly diff, poorly differentiated HCC; SUV, standardized uptake value.
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with 9.8-mm thick for the visual interpretation and quantitative analysis by using the standardized uptake value (SUV) which was calculated as follows:
Similarly coronal image of 9.8-mm thick were also reconstructed from attenuation-corrected transaxial images. All 18 F-FDG PET images were evaluated qualitatively by two experienced nuclear physicians in conjunction with CT and result was compared with clinical findings. In order to evaluate the 18 F-FDG uptake in the tumour, a 4x4 pixel square regions of interest (ROIs) were placed on the tumour, including the area of the highest activity but not covering the entire tumour. Positive lesions were identified if the uptake of 18 F-FDG in the tumour was higher than that in the background of the liver.
Statistical analysis. We analyzed data using Student's t-test to compare mean value of SUV between groups of patients. A linear regression analysis was performed to evaluate correlation of mean SUV with serum alpha-fetoprotein (AFP) concentration. Probability values of p<0.05 were considered significant.
Results

Relationship between
18 F-FDG uptake and histological findings. The results of 18 F-FDG PET and clinical finding of all patients before RFA are summarized in Table I . Among 24 patients, 12 (50%) were positive for 18 F-FDG PET prior to RFA.
18 F-FDG uptake and histological finding of all lesions were examined. Comparing 18 F-FDG uptake among different histological groups, poorly differentiated HCC and moderately differentiated HCC have high uptake of 18 F-FDG than well differentiated HCC (Fig. 1) . A significant difference in the SUV was observed between well differentiated HCC and moderately differentiated HCC (1.52±0.49, n=9 vs. 2.32±1.26, n=16, p=0.033) and also between well differentiated HCC and poorly differentiated HCC (1.52±0.49, n=9 vs. 2.94±1.54, n=8, p=0.037), however, not between moderately differentiated HCC and poorly differentiated HCC (2.32±1.26, n=16 vs. 2.94±1.54, n=8, p=0.349).
SUV of major tumours in 24 patients ranged from 1.27 to 5.64 (mean 2.61, n=24) and log value of AFP of these patients were compared with SUV (Fig. 2) . Significant correlation was observed between AFP and SUV before RFA (p=0.0431, r=0.4162, n=24). 18 F-FDG PET detected recurrence of HCC in 12 patients, where SUV at the time of initial PET study ranged from 1.34 to 5.64 (mean 3.16, n=12). The time interval between RFA and recurrence was divided in 4-6 months, 7-9 months and 10-18 months. There was inverse correlation between SUV and the interval between RFA and detection of recurrence indicating that a higher SUV may predict earlier recurrence of HCC. A significant difference was noted in SUV between patients who showed recurrence during 4-6 and 7-9 months (5.29±0.50 vs. 3.44±1.02, p=0.027), 4-6 and 10-18 months (5.29±0.50 vs. 1.69±0.45, p=0.013), and 7-9 and 10-18 months (3.44±1.02 vs. 1.69±0.45, p=0.007 as shown in Fig. 3 . Table II shows the numbers of patients with recurrence detected by 18 F-FDG PET and CT in a two-year follow-up period. No recurrence or new lesion was detected by 18 F-FDG PET and CT in the first 3 months after RFA. Between 4-6 months, 2 patients were positive by 18 F-FDG PET but they were negative by CT. Between 7-9 months, 6 patients were positive by 18 F-FDG PET while the CT showed only 4 positive. The patients with recurrence underwent second RFA within a month. Between 10-12 months, 18 F-FDG PET detected three recurrences with one having a metastasis to abdomen while CT showed recurrence in one patient. In first six months of the second year (13-18 months), 18 F-FDG PET detected one case with recurrence, one case with new lesion (in different segment of the liver) and one case with lung metastasis. In the same period CT detected three recurrences but was unable to detect the new lesion in the former patients. During last 6 months of the second year (19-24 months), 18 F-FDG PET did not detect any new lesion, while CT detected one lesion, which had been detected earlier by 18 F-FDG PET. A representative case of recurrent HCC is shown in (Fig. 4) .
Detection of recurrence.
Discussion
The results of the present study indicated that 18 F-FDG PET detected recurrence of HCC after RFA earlier than CT. Overall detection rate of recurrence with 18 F-FDG PET was 92% (11/12) and it was higher than that of CT 75% (9/12), suggesting that 18 F-FDG PET is a potential diagnostic tool for detection of the recurrence of HCC after RFA. None of the patients without abnormal 18 F-FDG uptake developed a local recurrence during the follow-up period of two years. Another advantage of 18 F-FDG PET over CT is its whole body imaging method, due to this we diagnosed extra hepatic metastasis in two patients in this study. We correctly found extrahepatic metastasis in the abdomen and another in the lung by PET and made a proper decision for the treatment, although chest CT was not performed in the case with pulmonary metastasis. 18 F-FDG PET and CT after radiofrequency ablation therapy in a two-year follow-up. ---------------------------------------------------------------------------------------------------- M, months after RFA; a One patient metastasized to the abdomen; b one patient developed a new lesion in a different segment of the liver; and c one patients metastasized to the lung.
- ----------------------------------------------------------------------------------------------------Figure 4 .
18 F-FDG PET and corresponded CT before and after RFA in a patient with hepatocellular carcinoma (patient no. 8). (A) 18 F-FDG PET shows abnormal uptake in the lesion (arrow) and the corresponding CT shows marginal enhancement (arrow). (B) 18 F-FDG PET after RFA shows no uptake of 18 F-FDG (arrow). (C) 18 F-FDG PET shows high uptake ofPreviously Donckier et al (17) reported that 18 F-FDG PET is a tool for early recognition of incomplete tumour destruction after RFA for liver metastasis and in another study Langenhoff et al (13) mentioned that 18 F-FDG PET accurately detected recurrence of colorectal liver metastasis earlier than CT, but to our knowledge there is no report yet on the value of 18 F-FDG PET as compared with conventional imaging modality to detect recurrence of HCC treated with RFA in a long followup period. The results of the preliminary study indicated that 18 F-FDG PET is a valuable tool to monitor the patients with HCC after RFA therapy to detect the recurrence earlier than CT in order to make a correct decision for the treatment.
In our study, poorly differentiated and moderately differentiated HCC have a higher 18 F-FDG uptake than well differentiated HCC and significant correlation was observed between SUV and histological differentiation as reported previously (11, 18) .
We found a significant correlation between the SUV in the HCC before RFA and the interval from the RFA to the time of recurrence which was detected by 18 F-FDG PET. Cases with high SUV showed recurrence significantly earlier than those with low SUV. Previous studies revealed that the tumour-to-normal ratio of SUV correlated with the survival of patients after surgery (19, 20) . The results of the present study indicate the possibility of the prognostic value of 18 F-FDG PET in patients with HCC undergoing RFA, and warrant further studies to evaluate it.
The limitations of our study were the retrospective nature, no exact protocol for the follow-up procedure, and a limited number of cases. In the present study we observed one false positive case with 18 F-FDG PET. This lesion turned out to be an infection. It is well known that 18 F-FDG is accumulated in inflammatory tissue therefore careful reading with reference to other modalities and clinical evaluation is needed.
In patients with HCC treated with RFA, 18 F-FDG PET detected recurrence earlier than CT and could diagnose extrahepatic lesions. 18 F-FDG uptake as evaluated with SUV showed a significant correlation with time of recurrence after RFA.
18 F-FDG PET may be a useful imaging modality as a follow-up procedure of HCC after RFA, in terms of early detection of recurrence and potential prognostic factor. An elaborated study with large number of patients with longer follow-up period will be needed to confirm the significance of these findings.
